These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

653 related articles for article (PubMed ID: 29475582)

  • 1. Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3Kα inhibition.
    Fan YH; Ding HW; Liu DD; Song HR; Xu YN; Wang J
    Bioorg Med Chem; 2018 May; 26(8):1675-1685. PubMed ID: 29475582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors.
    Fan YH; Li W; Liu DD; Bai MX; Song HR; Xu YN; Lee S; Zhou ZP; Wang J; Ding HW
    Eur J Med Chem; 2017 Oct; 139():95-106. PubMed ID: 28800461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3Kα.
    Ding HW; Deng CL; Li DD; Liu DD; Chai SM; Wang W; Zhang Y; Chen K; Li X; Wang J; Song SJ; Song HR
    Eur J Med Chem; 2018 Feb; 146():460-470. PubMed ID: 29407971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and Synthesis of Coumarin Derivatives as Novel PI3K Inhibitors.
    Ma CC; Liu ZP
    Anticancer Agents Med Chem; 2017; 17(3):395-403. PubMed ID: 26902599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Difuran-substituted quinoxalines as a novel class of PI3Kα H1047R mutant inhibitors: Synthesis, biological evaluation and structure-activity relationship.
    Zhang N; Yu Z; Yang X; Zhou Y; Tang Q; Hu P; Wang J; Zhang SL; Wang MW; He Y
    Eur J Med Chem; 2018 Sep; 157():37-49. PubMed ID: 30071408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2,4-Disubstituted quinazolines targeting breast cancer cells via EGFR-PI3K.
    Li ED; Lin Q; Meng YQ; Zhang LY; Song PP; Li N; Xin JC; Yang P; Bao CN; Zhang DQ; Zhang Y; Wang JK; Zhang QR; Liu HM
    Eur J Med Chem; 2019 Jun; 172():36-47. PubMed ID: 30939352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates bearing sulfonylpiperazine as antitumor inhibitors targeting PI3Kα.
    Yin Y; Sha S; Wu X; Wang SF; Qiao F; Song ZC; Zhu HL
    Eur J Med Chem; 2019 Nov; 182():111630. PubMed ID: 31446244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of novel series of 2H-benzo[b][1,4]oxazin-3(4H)-one and 2H-benzo[b][1,4]oxazine scaffold derivatives as PI3Kα inhibitors.
    Dong FD; Liu DD; Deng CL; Qin XC; Chen K; Wang J; Song HR; Ding HW
    Bioorg Med Chem; 2018 Aug; 26(14):3982-3991. PubMed ID: 29937355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, biological evaluation and structure-activity relationship of a novel class of PI3Kα H1047R mutant inhibitors.
    Zhang N; Yu Z; Yang X; Zhou Y; Wang J; Zhang SL; Wang MW; He Y
    Eur J Med Chem; 2018 Oct; 158():707-719. PubMed ID: 30245395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and antitumor activities evaluation of m-(4-morpholinoquinazolin-2-yl)benzamides in vitro and in vivo.
    Wang XM; Xin MH; Xu J; Kang BR; Li Y; Lu SM; Zhang SQ
    Eur J Med Chem; 2015; 96():382-95. PubMed ID: 25911625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fangchinoline derivatives induce cell cycle arrest and apoptosis in human leukemia cell lines via suppression of the PI3K/AKT and MAPK signaling pathway.
    Yang J; Hu S; Wang C; Song J; Chen C; Fan Y; Ben-David Y; Pan W
    Eur J Med Chem; 2020 Jan; 186():111898. PubMed ID: 31784186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents.
    Peng W; Tu ZC; Long ZJ; Liu Q; Lu G
    Eur J Med Chem; 2016 Jan; 108():644-654. PubMed ID: 26731167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
    Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
    Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of novel 2,4-disubstituted quinazoline derivatives targeting H1975 cells via EGFR-PI3K signaling pathway.
    Wang Z; Liu L; Dai H; Si X; Zhang L; Li E; Yang Z; Chao G; Zheng J; Ke Y; Lihong S; Zhang Q; Liu H
    Bioorg Med Chem; 2021 Aug; 43():116265. PubMed ID: 34192644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
    Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel 1,3,5-triazine derivatives as potent inhibitor of cervical cancer via dual inhibition of PI3K/mTOR.
    Hu J; Zhang Y; Tang N; Lu Y; Guo P; Huang Z
    Bioorg Med Chem; 2021 Feb; 32():115997. PubMed ID: 33440319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
    Chang J; Ren H; Zhao M; Chong Y; Zhao W; He Y; Zhao Y; Zhang H; Qi C
    Eur J Med Chem; 2017 Sep; 138():669-688. PubMed ID: 28711702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of thieno[3,2-d]pyrimidine derivatives containing aroyl hydrazone or aryl hydrazide moieties for PI3K and mTOR dual inhibition.
    Han Y; Tian Y; Wang R; Fu S; Jiang J; Dong J; Qin M; Hou Y; Zhao Y
    Bioorg Chem; 2020 Nov; 104():104197. PubMed ID: 32927132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
    Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
    Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel isoniazid-hydrazone derivatives induce cell growth inhibition, cell cycle arrest and apoptosis via mitochondria-dependent caspase activation and PI3K/AKT inhibition.
    Rouzi K; Altay A; Bouatia M; Yeniçeri E; Islam MS; Oulmidi A; El Karbane M; Karrouchi K
    Bioorg Chem; 2024 Sep; 150():107563. PubMed ID: 38885547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.